Get access to our best features
Get Started
SubscribeLogin
Get access to our best features
Get Started
Published

Teva Pharm tops quarterly estimates but 2025 earnings outlook falls short - Regional Media News

Summary by regionalmedianews.com
By Steven Scheer JERUSALEM (Reuters) -Teva Pharmaceutical Industries reported a slightly larger than expected rise in fourth-quarter profit, helped by double-digit sales gains in a trio of its branded drugs to treat migraines, Huntington’s disease and schizophrenia. The world’s largest generic drugmaker said on Wednesday it earned 71 cents per diluted share excluding one-off items in the October-December quarter, down from $1.00 per share a year…
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Similar News Topics

Business

Business

Inflation Reduction Act

Inflation Reduction Act

Israel

Israel

Israel Economy

Israel Economy

Trending Topics
App Store IconPlay Store Icon
CompanyAboutHistoryMissionBlogTestimonialsGroup SubscriptionsSubscribeGiftFree TrialCareersAffiliates
HelpHelp CenterFAQContact UsFor Educators/LibrariesMedia Bias RatingsOwnership and Factuality RatingsReferral CodeNews SourcesTopics
ToolsAppBrowser ExtensionDaily NewsletterBlindspot Report NewsletterBurst Your Bubble NewsletterTimelines
DonatePrivacy PolicyManage CookiesTerms and Conditions
© 2025 Snapwise Inc
News
For You
Search
BlindspotLocal